A Study of ONO-1110 in Patients With Postherpetic Neuralgia

Last updated: February 19, 2025
Sponsor: Ono Pharmaceutical Co. Ltd
Overall Status: Active - Recruiting

Phase

2

Condition

Postherpetic Neuralgia

Pain (Pediatric)

Pain

Treatment

ONO-1110

Placebo

Clinical Study ID

NCT06708416
ONO-1110-04
jRCT2031240504
  • Ages > 18
  • All Genders

Study Summary

To evaluate the efficacy and safety of ONO-1110 in Japanese patients with postherpetic neuralgia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Japanese (both sexes)

  • Age (at the time of informed consent): 18 years and older

  • Outpatient

  • Patients with persistent pain ≥3 months (90 days) after the onset of herpes zoster

  • Patients who are considered capable of understanding the study procedures andcompleting the pain diary and questionnaires appropriately by the investigator (sub-investigator)

Exclusion

Exclusion Criteria:

  • Patients who previously underwent neurodestruction or neurosurgical therapy for PHN

  • Patients with pain other than PHN that may affect assessments in this study

  • Patients with any skin condition related to the site of herpes zoster that mayaffect assessments in this study

  • Patients with a past history of or concurrent neurologic diseases that may affectassessments in this study

  • Patients with concurrent psychiatric diseases that may affect assessments in thisstudy

Study Design

Total Participants: 140
Treatment Group(s): 2
Primary Treatment: ONO-1110
Phase: 2
Study Start date:
February 12, 2025
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • Medical Corporation Fujigaki Clinic

    Ōita,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.